Emergency Contraception Clinical Trial
— COLIECOfficial title:
A Prospective Trial of the Copper T380 IUD or Oral Levonorgestrel and the Levonorgestrel IUD Initiated With Emergency Contraception
Verified date | August 2016 |
Source | University of Utah |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Observational |
The purpose of this study is to see how often women who come to a family planning clinic for emergency contraception, the morning after pill, are willing to use either the copper IUD or the levonorgestrel IUD. The investigators will also see if pregnancies occur in those choosing the levonorgestrel IUD and if people continue to use the IUD for 1 year.
Status | Completed |
Enrollment | 188 |
Est. completion date | February 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 35 Years |
Eligibility |
Inclusion Criteria:1. Between 18-35 years old 2. In need of EC (had unprotected intercourse within 120 hours - 5 days) 3. Desire to prevent pregnancy for 1 year 4. Fluent in English and/or Spanish 5. Have a regular menstrual cycle (24-35 days) 6. Know their last menstrual period (+/-3 days) 7. Be willing to comply with the study requirements 8. Participants current preferred phone number must be functioning at the time of study entry and will be tested prior to enrollment Exclusion Criteria: - 1. Current pregnancy 2. Breastfeeding 3. Intrauterine infection within the past 3 months 4. Sterilization 5. Already have an IUD or contraceptive implant (Implanon) in place 6. Vaginal bleeding of unknown etiology 7. Known Gonorrhea or Chlamydia infection in the last 30 days (unless successfully treated at least 7 days prior to study entry) 8. Allergy to LNG (for LNG IUD patients) 9. Allergy to copper or Wilson's disease (for Copper IUD patients) 10. Known abnormalities of the uterus that distort the uterine cavity |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Planned Parenthood Association of Utah | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
University of Utah |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Willingness to be randomized to either the copper or levonorgestrel IUD for emergency contraception. | We will query all participants to see if they would be willing to participate in a randomized study where the type of IUD (copper vs. levonorgestrel) was chosen at random. | At enrollment | No |
Primary | Pregnancy rates in first month after IUD insertion | Participants will have a urine pregnancy test at the clinic. They will also be given a home urine pregnancy test to check if they are not able to return to clinic and will give results by phone or electronic communication. | 4 weeks | Yes |
Secondary | 1 Year IUD continuation rates | IUD continuation rates will be compared between those who selected the copper IUD and thos who selected the levonorgestrel IUD | 1 year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00271583 -
Efficacy Trial of CDB 2914 for Emergency Contraception
|
Phase 2/Phase 3 | |
Completed |
NCT00777556 -
Emergency Contraception Actual Use Study
|
Phase 3 | |
Completed |
NCT00677755 -
Medical Abortion for Emergency Contraception Failure
|
N/A | |
Recruiting |
NCT06162611 -
Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo
|
Phase 4 | |
Completed |
NCT00411684 -
Safety and Efficacy of CDB-2914 for Emergency Contraception
|
Phase 3 | |
Completed |
NCT01569737 -
Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella
|
||
Completed |
NCT03208985 -
A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions
|
Phase 3 | |
Completed |
NCT02078414 -
Continued Use of Effective Contraception After Use of Emergency Contraception
|
||
Completed |
NCT01569113 -
Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo.
|
Phase 4 | |
Recruiting |
NCT03120728 -
Application for the Etonogestrel/Ethinyl Estradiol Ring
|
Phase 4 | |
Active, not recruiting |
NCT02076217 -
Quick Start of Highly Effective Contraception
|
||
Not yet recruiting |
NCT04172584 -
Awareness & Use of Emergency Contraception
|
||
Completed |
NCT03395756 -
Depot Medroxyprogesterone Acetate as Emergency Contraception
|
Early Phase 1 | |
Completed |
NCT03614494 -
Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception
|
Phase 2/Phase 3 |